The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
Open accessAbstract
BACKGROUND: Anemia is associated with an increased risk of cardiovascular and renal events among patients with type 2 diabetes and chronic kidney disease. Although darbepoetin alfa can effectively increase hemoglobin levels, its effect on clinical outcomes in these patients has not been adequately tested. METHODS: In this study involving 4038 patients with diabetes, chronic kidney disease, and anemia, we randomly assigned 2012 patients to darbepoetin alfa to achieve a hemoglobin level of approximately 13 g per deciliter and 2026 patients to placebo, with rescue darbepoetin alfa when the hemoglobin level was less than 9.0 g per deciliter. The primary end points were the composite outcomes of death or a cardiovascular event (nonfatal myocardial infarction, congestive heart failure, stroke, or hospitalization for myocardial ischemia) and of death or end-stage renal disease. RESULTS: Death or a cardiovascular event occurred in 632 patients assigned to darbepoetin alfa and 602 patients assigned to placebo (hazard ratio for darbepoetin alfa vs. placebo, 1.05; 95% confidence interval [CI], 0.94 to 1.17; P=0.41). Death or end-stage renal disease occurred in 652 patients assigned to darbepoetin alfa and 618 patients assigned to placebo (hazard ratio, 1.06; 95% CI, 0.95 to 1.19; P=0.29). Fatal or nonfatal stroke occurred in 101 patients assigned to darbepoetin alfa and 53 patients assigned to placebo (hazard ratio, 1.92; 95% CI, 1.38 to 2.68; P<0.001). Red-cell transfusions were administered to 297 patients assigned to darbepoetin alfa and 496 patients assigned to placebo (P<0.001). There was only a modest improvement in patient-reported fatigue in the darbepoetin alfa group as compared with the placebo group. CONCLUSIONS: The use of darbepoetin alfa in patients with diabetes, chronic kidney disease, and moderate anemia who were not undergoing dialysis did not reduce the risk of either of the two primary composite outcomes (either death or a cardiovascular event or death or a renal event) and was associated with an increased risk of stroke. For many persons involved in clinical decision making, this risk will outweigh the potential benefits. (ClinicalTrials.gov number, NCT00093015.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In pre-dialysis CKD patients with or without diabetes higher Hgb targets, particularly in patients with poor initial Hgb responses, were also associated with increased cardiovascular risk.”
From Regulation of erythropoiesis by hypoxia-inducible factors (2013) · cites this paper as [229]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Self-citationStamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Self-citationCorrection of anemia with epoetin alfa in chronic kidney disease
Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., & Reddan, D. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065485 · Cited by 2,762
Self-citationNormalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia
Drüeke, T. B., Locatelli, F., Clyne, N., Eckardt, K., Macdougall, I. C., Tsakiris, D., Burger, H.-U., & Scherhag, A. W. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062276 · Cited by 2,094
Self-citationEschbach, J. W., Abdulhadi, M. H., Browne, J. K., Delano, B. G., Downing, M. R., Egrie, J. C., Evans, R. W., Friedman, E. A., Graber, S. E., Haley, N. R., et al. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-12-992 · Cited by 795
Blood Pressure Lowering Treatment Trialists’ Collaboration (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.12.1410 · Cited by 789
Booth, G. L., Kapral, M. K., Fung, K., & Tu, J. V. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68967-8 · Cited by 782
Flagged first, then by citations
Research works printed but not linked: 2
- Pfeffer MA, 2005, Rev Cardiovasc Med, 3, S35
- Strippoli GF, 2006, Cochrane Database Syst Rev, 4, CD003967
Cited by
Sorted by citations
Items 501–600 of 1,000
Zhou, J., Wei‐jie, Y., Zhu, N., Zhou, Y., & Wang, L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043655 · Cited by 38
Hepcidin in anemia of chronic kidney disease: review for the pediatric nephrologist
Atkinson, M. A., & White, C. T. (2011) · Pediatric Nephrology · doi:10.1007/s00467-011-1832-y · Cited by 37
Fabbro, P. D., Luthi, J., Carrera, E., Michel, P., Burnier, M., & Burnand, B. (2010) · BMC Nephrology · doi:10.1186/1471-2369-11-27 · Cited by 37
Lamerato, L. E., James, G., van Haalen, H., Hedman, K., Sloand, J. A., Tang, A., Wittbrodt, E. T., & Yee, J. (2022) · BMC Nephrology · doi:10.1186/s12882-022-02778-8 · Cited by 36
Babitt, J. L., Berns, J. S., Bozkurt, B., Khedairy, R. S. C., Cuevas, Y., Effa, E. E., Eisenga, M. F., Fishbane, S., Ginzburg, Y. Z., Haase, V. H., et al. (2026) · Kidney International · doi:10.1016/j.kint.2025.06.005 · Cited by 36
Darbepoetin for the anaemia of chronic kidney disease
Palmer, S. C., Saglimbene, V. M., Craig, J. C., Navaneethan, S. D., & Strippoli, G. F. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009297.pub2 · Cited by 37
Bonner, A., Caltabiano, M. L., & Berlund, L. (2013) · Nursing and Health Sciences · doi:10.1111/nhs.12038 · Cited by 36
Race and ethnicity influences on cardiovascular and renal events in patients with diabetes mellitus
Lewis, E. F., Claggett, B. L., Parfrey, P. S., Burdmann, E. A., McMurray, J. J. V., Solomon, S. D., Levey, A. S., Ivanovich, P. T., Eckardt, K., Kewalramani, R., et al. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.05.008 · Cited by 36
Self-citationTomey, M. I., & Winston, J. A. (2014) · Annals of Global Health · doi:10.1016/j.aogh.2013.12.007 · Cited by 38
Shah, A. D., Nicholas, O., Timmis, A., Feder, G. S., Abrams, K. R., Chen, R., Hingorani, A. D., & Hemingway, H. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1000439 · Cited by 37
Posttransplant anemia in solid organ recipients
Blosser, C. D., & Bloom, R. D. (2010) · Transplantation Reviews · doi:10.1016/j.trre.2010.01.006 · Cited by 36
Kang, J., Park, J., Lee, J. M., Park, J. J., & Choi, D. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.04.187 · Cited by 37
Wang, C., Kane, R. C., Levenson, M. S., Kelman, J. A., Wernecke, M., Lee, J., Kozlowski, S., Dekmezian, C., Zhang, Z., Thompson, A., et al. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.6520 · Cited by 37
Iron deficiency in chronic and acute heart failure: A contemporary review on intertwined conditions
Cunha, G., Rocha, B. M. L., & Falcão, L. M. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2018.04.013 · Cited by 36
“Is It Removed During Dialysis?”—Cognitive Dysfunction in Advanced Kidney Failure—A Review Article
Crowe, K., Quinn, T. J., Mark, P. B., & Findlay, M. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.787370 · Cited by 39
Farrington, D. K., Sang, Y., Grams, M. E., Ballew, S. H., Dunning, S. C., Stempniewicz, N., & Coresh, J. (2022) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2022.07.014 · Cited by 36
Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease
Saglimbene, V. M., Palmer, S. C., Ruospo, M., Natale, P., Craig, J. C., & Strippoli, G. F. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009904.pub2 · Cited by 36
Risk of Sudden Cardiac Death in Chronic Kidney Disease
Poulikakos, D. J., Banerjee, D., & Malík, M. (2013) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.12328 · Cited by 35
Spiegel, D., Macdougall, I. C., Norris, L. B., Qureshi, Z. P., Sartor, O. A., Lai, S. Y., Tallman, M. S., Raisch, D. W., Smith, S. W., Silver, S. M., et al. (2012) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0032-1328884 · Cited by 35
van der Weerd, N. C., den Hoedt, C. H., Blankestijn, P. J., Bots, M. L., van den Dorpel, M. A., Levesque, R. L., Mazairac, A. H. A., Nubé, M. J., Penne, E. L., ter Wee, P. M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094434 · Cited by 35
Erythropoietin and the heart: facts and perspectives
Mastromarino, V., Volpe, M., Musumeci, B., Autore, C., & Conti, E. (2010) · Clinical Science · doi:10.1042/cs20100305 · Cited by 35
Ogino, A., Takemura, G., Kawasaki, M., Tsujimoto, A., Kanamori, H., Li, L., Goto, K., Maruyama, R., Kawamura, I., Takeyama, T., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.04.068 · Cited by 35
Fuller, D. S., Bieber, B. A., Pisoni, R. L., Li, Y., Morgenstern, H., Akizawa, T., Jacobson, S. H., Locatelli, F., Port, F. K., & Robinson, B. M. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015060673 · Cited by 35
Rheault, M. N., Molony, J. T., Nevins, T. E., Herzog, C. A., & Chavers, B. M. (2016) · Kidney International · doi:10.1016/j.kint.2016.09.013 · Cited by 35
SGLT2 inhibitors – a potential treatment for Alport syndrome
Mabillard, H. R., & Sayer, J. A. (2020) · Clinical Science · doi:10.1042/cs20191276 · Cited by 36
Charytan, D. M., Lewis, E. F., Desai, A. S., Weinrauch, L. A., Ivanovich, P. T., Toto, R. D., Claggett, B. L., Liu, J., Hartley, L. H., Finn, P. V., et al. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.02.324 · Cited by 35
Self-citationPerformance Measurement in Chronic Kidney Disease
Smith, K. A., & Hayward, R. A. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010111152 · Cited by 35
Zhang, L., Gong, A. G. W., Riaz, K., Deng, J. Y., Ho, C., Lin, H. Q., Dong, T. T.-X., Lee, Y.-K., & Tsim, K. W. K. (2016) · FEBS Open Bio · doi:10.1002/2211-5463.12146 · Cited by 35
The investigation and treatment of secondary anaemia
Davis, S. L., & Littlewood, T. J. (2011) · Blood Reviews · doi:10.1016/j.blre.2011.10.003 · Cited by 34
mTOR inhibition and erythropoiesis: microcytosis or anaemia?
Diekmann, F., Rovira, J., Díaz‐Ricart, M., Arellano, E. M., Vodenik, B., Jou, J. M., Corrons, J. V., Escolar, G., & Campistol, J. M. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr318 · Cited by 34
Distinct immunologic effects of different intravenous iron preparations on monocytes
Fell, L. H., Zawada, A. M., Rogacev, K. S., Seiler, S., Fliser, D., & Heine, G. H. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft524 · Cited by 34
Hafer, C., Becker, T., Kielstein, J. T., Bahlmann, E., Schwarz, A., Grinzoff, N., Drzymala, D., Bonnard, I., Richter, N., Lehner, F., et al. (2011) · Kidney International · doi:10.1038/ki.2011.349 · Cited by 34
Lullo, L. D., Ronco, C., Cozzolino, M. G., Russo, D., Russo, L., Iorio, B. R. D., Pascalis, A. D., Bàrbera, V., Galliani, M., Vitaliano, E., et al. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.04.027 · Cited by 34
Zheng, Q., Yang, H., Fu, X., Huang, Y., Wei, R., Wang, Y., Liu, Y., & Liu, W. J. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa110 · Cited by 34
Lau, J. H., Gangji, A. S., Rabbat, C. G., & Brimble, K. S. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq330 · Cited by 34
Palmer, S. C., Salanti, G., Craig, J. C., Mavridis, D., & Strippoli, G. F. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010590 · Cited by 34
Suttorp, M., Hoekstra, T., Rotmans, J. I., Ott, I., Mittelman, M., Krediet, R. T., & Dekker, F. W. (2013) · BMC Nephrology · doi:10.1186/1471-2369-14-200 · Cited by 33
Management of anemia with erythropoietic-stimulating agents in children with chronic kidney disease
Warady, B. A., & Silverstein, D. M. (2013) · Pediatric Nephrology · doi:10.1007/s00467-013-2557-x · Cited by 33
Erythropoietin: The swinging pendulum
Oster, H. S., Neumann, D., Hoffman, M. A., & Mittelman, M. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.04.017 · Cited by 33
Investigational therapies for renal disease-induced anemia
Schmid, H., & JELKMANN, W. E. B. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1182981 · Cited by 33
Tseng, W., Liu, J., Hung, S., Kuo, K., Chen, Y., Tarng, D., & Hsu, C. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.03.080 · Cited by 33
Toto, R. D. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017121317 · Cited by 33
Self-citationEisenga, M. F., de Jong, M. A., van der Meer, P., Leaf, D. E., Huls, G. A., Nolte, I. M., Gaillard, S., Bakker, S. J. L., & de Borst, M. H. (2019) · PLoS Medicine · doi:10.1371/journal.pmed.1002818 · Cited by 34
Guedes, M. H., Guetter, C. R., Erbano, L. H. O., Palone, A. G., Zee, J., Robinson, B. M., Pisoni, R. L., de Moraes, T. P., Pecoits‐Filho, R., & Baena, C. P. (2020) · BMC Nephrology · doi:10.1186/s12882-020-01912-8 · Cited by 33
A critical review of chronic kidney disease as a risk factor for coronary artery disease
Coyle, M., Flaherty, G. T., & Jennings, C. S. (2021) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2021.100822 · Cited by 35
Targeting Cardiovascular Risk Factors Through Dietary Adaptations and Caloric Restriction Mimetics
Voglhuber, J., Ljubojević-Holzer, S., Abdellatif, M., & Sedej, S. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.758058 · Cited by 34
Inrig, J. K., Bryskin, S. K., Patel, U. D., Arcasoy, M. O., & Szczech, L. A. M. (2011) · BMC Nephrology · doi:10.1186/1471-2369-12-67 · Cited by 33
Meeting KDOQI Guideline Goals at Hemodialysis Initiation and Survival during the First Year
Slinin, Y., Guo, H., Gilbertson, D. T., Mau, L., Ensrud, K. E., Rector, T. S., Collins, A. J., & Ishani, A. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01320210 · Cited by 33
Roxadustat and Anemia of Chronic Kidney Disease
Kaplan, J. (2019) · New England Journal of Medicine · doi:10.1056/nejme1908978 · Cited by 33
Reduction of cardiovascular risk in chronic kidney disease by mineralocorticoid receptor antagonism
Epstein, M. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00289-2 · Cited by 33
Minutolo, R., Zamboli, P., Chiodini, P., Mascia, S., Vitiello, S., Stanzione, G., Bertino, V., Conte, G., & Nicola, L. D. (2010) · Blood Purification · doi:10.1159/000321486 · Cited by 32
Intravenous iron supplementation after kidney transplantation
Rozen‐Zvi, B., Gafter‐Gvili, A., Zingerman, B. V., Levy‐Drummer, R. S., Levy, L., Mor, E., Gafter, U., & Rahamimov, R. (2012) · Clinical Transplantation · doi:10.1111/j.1399-0012.2012.01602.x · Cited by 32
Pérgola, P. E., Pecoits‐Filho, R., Winkelmayer, W. C., Spinowitz, B., Rochette, S., Thompson‐Leduc, P., Lefèbvre, P., Shafai, G., Bozas, A., Sanon, M., et al. (2019) · PharmacoEconomics - Open · doi:10.1007/s41669-019-0132-5 · Cited by 32
Iron Deficiency in CKD Without Concomitant Anemia
Wish, J. B., Anker, S. D., Butler, J., Cases, A., Stack, A. G., & Macdougall, I. C. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.07.032 · Cited by 34
Caring for the pregnant kidney transplant recipient
Concepcion, B. P., & Schaefer, H. M. (2011) · Clinical Transplantation · doi:10.1111/j.1399-0012.2011.01492.x · Cited by 32
Cardio-Renal Syndrome Type 4: Epidemiology, Pathophysiology and Treatment
House, A. A. (2012) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2011.11.006 · Cited by 33
Aspinall, S. L., Cunningham, F. E., Zhao, X., Boresi, J., Tonnu-Mihara, I. Q., Smith, K. J., Stone, R. A., & Good, C. B. (2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.04.013 · Cited by 32
Fort, J., Cuevas, X. D. L., López, F. J. G., Pérez‐García, R., Llados, F., Lozano, J., Martín‐Malo, A., & on behalf of all investigators from the ANSWER study (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq073 · Cited by 32
Modulation of stroke risk in chronic kidney disease
Arnold, J. J., Sims, D., & Ferro, C. J. (2015) · Clinical Kidney Journal · doi:10.1093/ckj/sfv136 · Cited by 32
Measurement of iron status in chronic kidney disease
Hayes, W. N. (2018) · Pediatric Nephrology · doi:10.1007/s00467-018-3955-x · Cited by 32
FGF23 antagonism: the thin line between adaptation and maladaptation in chronic kidney disease
Ketteler, M., Biggar, P. H., & Liangos, O. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs557 · Cited by 31
Manito, N., Cerqueiro, J. M., Colet, J. C., García‐Pinilla, J. M., Franco, Á. G., Amorós, J. G., Peraira, J. R., & Manzano, L. (2016) · Revista Clínica Española · doi:10.1016/j.rce.2016.08.001 · Cited by 31
Treatment of renal anemia: Erythropoiesis stimulating agents and beyond
Biggar, P. H., & Kim, G. (2017) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.2017.36.3.209 · Cited by 31
Park, H., Liu, X., Henry, L. L., Harman, J. S., & Ross, E. A. (2018) · BMC Nephrology · doi:10.1186/s12882-018-1119-7 · Cited by 31
Eckardt, K., Agarwal, R., Farag, Y. M. K., Jardine, A. G., Khawaja, Z., Koury, M. J., Luo, W. F., Matsushita, K., McCullough, P. A., Parfrey, P. S., et al. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa204 · Cited by 31
Self-citationInterventions for fatigue in people with kidney failure requiring dialysis
Natale, P., Ju, A., Strippoli, G. F., Craig, J. C., Saglimbene, V. M., Unruh, M. L., Stallone, G., & Jauré, A. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013074.pub2 · Cited by 31
Nervous system disorders in dialysis patients
Bansal, V., & Bansal, S. (2013) · Handbook of clinical neurology · doi:10.1016/b978-0-7020-4086-3.00025-4 · Cited by 31
Briet, M. B., Barhoumi, T., Mian, M. O. R., Sierra, C., Boutouyrie, P., Davidman, M., Bercovitch, D. D., Nessim, S. J., Frisch, G., Paradis, P., et al. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000128 · Cited by 32
McMurray, J. J. V., Anand, I. S., Díaz, R., Maggioni, A. P., O’Connor, C. M., Pfeffer, M. A., Solomon, S. D., Tendera, M., van Veldhuisen, D. J., Albizem, M. B., et al. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs204 · Cited by 31
Self-citationShukla, A. M., Bose, C., Karaduta, O. K., Apostolov, E. O., Kaushal, G. P., Fahmi, T., Segal, M. S., & Shah, S. V. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139226 · Cited by 32
Akaishi, M., Hiroe, M., Hada, Y., Suzuki, M., Tsubakihara, Y., & Akizawa, T. (2013) · Journal of Cardiology · doi:10.1016/j.jjcc.2013.04.008 · Cited by 31
High‐dose erythropoietin for tissue protection
Lund, A., Lundby, C., & Olsen, N. V. (2014) · European Journal of Clinical Investigation · doi:10.1111/eci.12357 · Cited by 30
Anemia and Iron Deficiency in Heart Failure
Arora, N. P., & Ghali, J. K. (2014) · Heart Failure Clinics · doi:10.1016/j.hfc.2013.11.002 · Cited by 30
Causland, F. R. M., Claggett, B. L., Burdmann, E. A., Chertow, G. M., Cooper, M. E., Eckardt, K., Ivanovich, P. T., Levey, A. S., Lewis, E. F., McGill, J. B., et al. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2018.10.006 · Cited by 30
Self-citationProvenzano, R., Tumlin, J. A., Zabaneh, R. I., Chou, J., Hemmerich, S., Neff, T. B., & Yu, K. H. P. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1648 · Cited by 31
Barbieri, M., Chiodini, P., Gennaro, P. D., Hafez, G., Liabeuf, S., Małyszko, J., Mani, L., Mattace-Raso, F. U. S., Pépin, M., Perico, N., et al. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107146 · Cited by 30
Self-citationIto, H., Takeuchi, Y., Ishida, H., Otawa, A., Shibayama, A., Antoku, S., Abe, M., Mifune, M., & Togane, M. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00060.x · Cited by 30
Erythropoiesis-Stimulating Agents in Renal Medicine
Locatelli, F., & Vecchio, L. D. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-s3-19 · Cited by 30
Garlo, K. G., Williams, D., Lucas, L., Wong, R., Botler, J., Abramson, S., & Parker, M. G. (2015) · Medicine · doi:10.1097/md.0000000000000964 · Cited by 30
Streja, E., Park, J., Chan, T.-Y., Lee, J. S., Soohoo, M., Rhee, C. M., Arah, O. A., & Kalantar‐Zadeh, K. (2016) · International Journal of Nephrology · doi:10.1155/2016/6087134 · Cited by 30
Inrig, J. K., Sapp, S. K., Barnhart, H. X., Patel, U. D., Reddan, D. N., Singh, A. K., Califf, R. M., & Szczech, L. A. M. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs123 · Cited by 30
Self-citationKleikers, P. W. M., Hooijmans, C. R., Göb, E., Langhauser, F., Rewell, S. S. J., Radermacher, K. A., Ritskes-Hoitinga, M. J., Howells, D. W., Kleinschnitz, C., & Schmidt, H. H. H. W. (2015) · Scientific Reports · doi:10.1038/srep13428 · Cited by 29
Optimal hematocrit in an artificial microvascular network
Piety, N. Z., Reinhart, W. H., Stutz, J., & Shevkoplyas, S. S. (2017) · Transfusion · doi:10.1111/trf.14213 · Cited by 29
Petersen, J. Z., Schmidt, L. S., Vinberg, M., Jørgensen, M. B., Hageman, I., Ehrenreich, H., Knudsen, G. M., Kessing, L. V., & Miskowiak, K. W. (2018) · Trials · doi:10.1186/s13063-018-2995-7 · Cited by 29
High sensitivity Troponin-I levels in asymptomatic hemodialysis patients
Tarapan, T., Musikatavorn, K., Phairatwet, P., Takkavatakarn, K., Susantitaphong, P., Eiam‐Ong, S., & Tiranathanagul, K. (2019) · Renal Failure · doi:10.1080/0886022x.2019.1603110 · Cited by 31
The cardiovascular–dialysis nexus: the transition to dialysis is a treacherous time for the heart
Chan, K. T. K., Moe, S. M., Saran, R., & Libby, P. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa1049 · Cited by 32
Covic, A. C., Nistor, I., Donciu, M., Dumea, R., Bolignano, D., & Goldsmith, D. J. A. (2014) · American Journal of Nephrology · doi:10.1159/000366025 · Cited by 29
Designing drugs that combat kidney damage
Ramos, A. M., González‐Guerrero, C., Sanz, A. B., Sánchez-Niño, M. D., Rodríguez-Osorio, L., Martín-Cleary, C., Fernández‐Fernández, B., Ruiz‐Ortega, M., & Ortíz, A. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1033394 · Cited by 30
Predicting costs of care in heart failure patients
Smith, D. H., Johnson, E. S., Blough, D. K., Thorp, M. L., Yang, X., Petrik, A. F., & Crispell, K. A. (2012) · BMC Health Services Research · doi:10.1186/1472-6963-12-434 · Cited by 29
Prevalence and significance of stroke symptoms among patients receiving maintenance dialysis
Tamura, M. K., Meyer, J. B., Saxena, A. B., Huh, J. W. T., Wadley, V. G., & Schiller, B. M. (2012) · Neurology · doi:10.1212/wnl.0b013e31826845e9 · Cited by 29
Patient-Reported and Actionable Safety Events in CKD
Ginsberg, J. S., Zhan, M., Diamantidis, C. J., Woods, C. M., Chen, J., & Fink, J. C. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013090921 · Cited by 29
Complications of Diabetes Mellitus
Brownlee, M., Aiello, L. P., Cooper, M. E., Vinik, A. I., Plutzky, J., & Boulton, A. J. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00033-2 · Cited by 29
Self-citationFiocchi, E. H., Cowgill, L. D., Brown, D. C., Markovich, J. E., TUCKER, S. M., Labato, M. A., & Callan, M. B. (2017) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.14681 · Cited by 29
Sato, K., Kumagai, N., & Suzuki, N. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.01134 · Cited by 29
Darbepoetin Alfa in Patients with Advanced CKD without Diabetes: Randomized, Controlled Trial
Hayashi, T., Maruyama, S., Nangaku, M., Narita, I., Hirakata, H., Tanabe, K., Morita, S., Tsubakihara, Y., Imai, E., Akizawa, T., et al. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.08900719 · Cited by 30
The Comparative Short-term Effectiveness of Iron Dosing and Formulations in US Hemodialysis Patients
Kshirsagar, A. V., Freburger, J. K., Ellis, A. R., Wang, L. H.-C., Winkelmayer, W. C., & Brookhart, M. A. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.11.030 · Cited by 28
Suzuki, M., Hada, Y., Akaishi, M., Hiroe, M., Aonuma, K., Tsubakihara, Y., & Akizawa, T. (2012) · International Heart Journal · doi:10.1536/ihj.53.238 · Cited by 28
for the Regeneration of Vital Myocardium in ST-Segment Elevation Myocardial Infarction by Erythropoietin (REVIVAL-3) Study Investigators, Steppich, B., Groha, P., Ibrahim, T., Schunkert, H., Laugwitz, K., Hadamitzky, M., Kastrati, A., & Ott, I. (2017) · BMC Cardiovascular Disorders · doi:10.1186/s12872-016-0464-3 · Cited by 28
Contemporary outcomes of anemia in US patients with chronic kidney disease
Wittbrodt, E. T., James, G., Kumar, S. R., van Haalen, H., Chen, H., Sloand, J. A., & Kalantar‐Zadeh, K. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab195 · Cited by 28
Mallik, R., & Chowdhury, T. A. (2022) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188221081601 · Cited by 28
Metadata
- Authors
- Pfeffer, M. A., Burdmann, E. A., Chen, C.-Y., Cooper, M. E., de Zeeuw, D., Eckardt, K.-U., Feyzi, J. M., Ivanovich, P., Kewalramani, R., Levey, A. S., Lewis, E. F., McGill, J. B., McMurray, J. J. V., Parfrey, P., Parving, H.-H., Remuzzi, G., Singh, A. K., Solomon, S. D., & Toto, R.
- Affiliations
- Brigham and Women's Hospital (US)
- Hospital de Base (BR)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- University of Wisconsin–Madison (US)
- Northwestern University (US)
- Tufts University (US)
- Harvard University (US)
- Washington University in St. Louis (US)
- University of Glasgow (GB)
- University of Copenhagen (DK)
- The University of Texas Southwestern Medical Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-11-19
- Volume
- 361
- Issue
- 21
- Pages
- 2019-2032
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1998943227
- Cited by
- 2,096
- References
- 32
- Citations by year
- 2026: 62 · 2025: 66 · 2024: 65 · 2023: 94 · 2022: 92 · 2021: 128 · 2020: 121 · 2019: 111 · 2018: 90 · 2017: 108 · 2016: 125 · 2015: 122 · 2014: 163 · 2013: 174 · 2012: 175
- FWCI
- 125.33
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- Robert Wood Johnson Foundation
- Amgen
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Biogen
- Louisiana Board of Regents
- Boston Scientific Corporation
- McGill University
- Celladon Corporation
- Covis Pharma
- Cytokinetics
- Servier
- Genentech
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- darbepoetin alfa, type 2 diabetes, chronic kidney disease, anemia, erythropoiesis-stimulating agents, cardiovascular events, end-stage renal disease, stroke, red blood cell transfusion, fatigue, hemoglobin target, cardiovascular risk reduction, non-dialysis patients
- MeSH terms
- Darbepoetin alfa, Aged, Anemia, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Erythropoietin, Female, Hematinics, Hemoglobins, Humans, Kidney Failure, Chronic, Male, Middle Aged, Neoplasms, Stroke, Renal Insufficiency, Chronic, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
